What Compounded Semaglutide Actually Is, and What It Isn’t

For healthRX review, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.

A patient I worked with last fall, a 48-year-old administrative coordinator in Dallas, came to her first telehealth visit with a three-ring binder. She’d printed out Reddit threads, TikTok screenshots, a Novo Nordisk press release, and an article from a wellness blog that confidently mixed up semaglutide with tirzepatide. Her opening question: “Is the compounded version even the same drug?” That’s the question most people are really asking when they start researching this topic, and the answer is simpler than the internet makes it seem.

The active pharmaceutical ingredient in compounded semaglutide is the same molecule found in Ozempic and Wegovy. Same chemical structure, same mechanism in the body. What differs is the supply pathway. Brand-name products are FDA-approved finished products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a state-licensed or 503A compounding pharmacy for an individual patient under a clinician’s prescription. It has not been studied as a finished product in registrational trials and is not FDA-approved as a finished product.

That distinction matters. But it doesn’t mean what some people assume it means.

The Pharmacology in Brief

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is an incretin hormone your gut releases after you eat. The receptor for it sits on pancreatic beta cells, in appetite-regulating centers in the hypothalamus, and throughout the GI tract.

What semaglutide does, pharmacologically, is fairly elegant: it stimulates insulin secretion only when glucose is elevated (which is why hypoglycemia is uncommon on monotherapy), suppresses glucagon in the postprandial state, slows gastric emptying, and tamps down appetite at the level of the brain. The long half-life allows for once-weekly subcutaneous dosing, which is why the injection schedule works the way it does.

The clinical evidence base comes from two major trial programs. The STEP trials looked at weight management in adults with overweight or obesity. STEP-1 randomized 1,961 adults without diabetes to weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. The semaglutide arm lost approximately 14.9% of body weight from baseline, versus 2.4% in the placebo arm (Wilding et al., New England Journal of Medicine, 2021). Individual responses ranged widely, but the mean effect was large by the standards of obesity pharmacotherapy. STEP-3 layered in intensive behavioral therapy and showed a somewhat larger effect. STEP-5 followed patients for 104 weeks and reported sustained weight reduction.

The SUSTAIN program evaluated semaglutide in type 2 diabetes at lower doses (0.5 mg and 1.0 mg weekly, later 2.0 mg in SUSTAIN FORTE). SUSTAIN-6, the cardiovascular outcome trial, reported a reduction in the composite of major adverse cardiovascular events in a high-risk diabetes population (Marso SP et al.).

All of this trial data was generated using brand-name finished product. That’s important to acknowledge. It informs what we expect from the molecule, but it does not constitute a direct registrational study of compounded preparations.

Titration: What the Schedule Looks Like in Practice

The standard titration from the STEP trials and the Wegovy label goes like this: 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, and finally 2.4 mg weekly as the maintenance dose. Full escalation takes roughly sixteen to seventeen weeks.

Most compounded programs follow the same milligram steps. The catch is that concentrations vary by pharmacy, so the volume you draw into the syringe will differ between programs. The dose in milligrams is what matters clinically, not how many units you’re pulling from the vial. If you’re switching programs, confirm the milligram dose at each step. Don’t assume volumes translate.

The schedule isn’t a rigid conveyor belt. A patient struggling with nausea at 0.5 mg can sit at that dose for another four weeks before moving up. A patient doing well on 1.7 mg, meeting their clinical goals, losing weight steadily, tolerating the medication, can stay there indefinitely rather than pushing to 2.4 mg. The best programs treat the titration as a clinical decision, not a checkbox.

Storage is straightforward: refrigerate at 36 to 46 degrees Fahrenheit, limited time at room temperature for transport. Rotate injection sites between abdomen, thigh, and upper arm to reduce local irritation.

Side Effects: What’s Common, What’s Rare, What’s Serious

Gastrointestinal symptoms dominate the side-effect profile. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. These showed up consistently across the STEP and SUSTAIN programs and track in real-world cohorts too. The boring truth is that most of these symptoms are mild to moderate, concentrated in the first eight to twelve weeks, and resolve with continued therapy or a temporary dose hold. They’re unpleasant but manageable for most people.

The less common events deserve more attention. Gallbladder events can occur, especially with rapid weight loss (this is a weight-loss phenomenon, not strictly a semaglutide phenomenon, but the drug accelerates it). Acute pancreatitis is rare but requires immediate evaluation if you develop severe abdominal pain radiating to your back. The Wegovy and Ozempic labels carry a boxed warning about thyroid C-cell tumors observed in rodent studies; this has not been replicated in humans, but the warning exists, and it’s a contraindication in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).

Hypoglycemia is uncommon on semaglutide alone in non-diabetic patients because the insulin-stimulating effect is glucose-dependent. The risk goes up when semaglutide is combined with insulin or sulfonylureas, and in those cases, the concurrent medication dose often needs adjustment. Patients on warfarin or other drugs with narrow therapeutic windows should also discuss the slowed gastric emptying with their prescriber, since absorption timing can shift.

The Price Question

Let’s be direct: the reason most people end up looking at compounded semaglutide is cost.

Brand-name Wegovy and Ozempic carry list prices above $1,300 per month. Cash-pay rates at retail pharmacies generally land between $1,000 and $1,400. Insurance coverage for the weight-management indication is inconsistent at best. The diabetes indication gets better coverage, but it varies by plan.

Compounded programs in compliant telehealth structures price significantly lower. HealthRX, for example, runs $179.99 to $279.99 per month depending on dose, operates in 44 US states, and holds LegitScript certification. (More detail on their program structure is available in this HealthRX review.)

The pricing gap isn’t a mystery. Brand-name finished products carry the cost of massive clinical trial programs, FDA submissions, post-marketing surveillance, and Novo Nordisk’s commercial margin. Compounded preparations are produced at a different scale through a different regulatory pathway. The economics are structurally different, not suspicious.

HSA and FSA reimbursement for compounded semaglutide depends on the plan and the documentation the program provides. Confirm the invoicing format before you enroll if you plan to use those accounts.

How to Think About Compounded vs. Brand-Name

This is where I think the conversation goes wrong most often. People want a winner. Compounded good, brand bad. Or: brand real, compounded sketchy. Neither framing is accurate.

The clinical evidence from STEP and SUSTAIN was generated with brand-name finished product. That’s a fact. The manufacturing oversight model is different for compounded pharmacies, which are regulated by state boards of pharmacy (and, for 503B outsourcing facilities, by the FDA under a separate framework). Adverse-event surveillance is less complete for compounded preparations. These are real differences.

But compounding is a long-established part of pharmaceutical practice across many drug classes. It’s not some rogue operation. The framework for understanding the two pathways is different, and a responsible reference names those differences rather than collapsing them into a sales pitch in either direction.

My honest opinion: the most important variable isn’t which pathway you choose. It’s the clinical structure around the medication. A compounded program with proper intake screening, lab work, titration oversight, and follow-up is a better experience than a brand-name prescription written by a provider who hands you a pen and says “good luck.” (The reverse is also true, obviously.)

When to Call Your Clinician

Some situations need real-time clinical input, not Googling.

Persistent severe abdominal pain, especially with radiation to the back or fever: call now. Inability to keep down fluids for more than 24 hours, signs of dehydration, persistent vomiting: call now. New gallbladder symptoms (right upper quadrant pain after eating, jaundice): get evaluated. Reflux that doesn’t respond to meal-timing changes is worth raising at your next check-in. So are mood changes, including new or worsening depressive symptoms.

Pregnancy, planned pregnancy, or breastfeeding: have the conversation before your next dose. Personal or family history of medullary thyroid carcinoma or MEN2 is a hard contraindication and should have been caught at intake. If it wasn’t, that’s a conversation to have immediately.

Frequently Asked Questions

Is compounded semaglutide the same drug as Ozempic and Wegovy?

The active ingredient is the same molecule. The finished product, regulatory category, and manufacturing pathway differ. Brand-name products are FDA-approved and manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient and is not FDA-approved as a finished product.

How long does treatment typically last?

STEP-1 captured 68 weeks; STEP-5 extends to 104 weeks. Clinical experience now goes beyond two years. Duration is individualized based on goals, response, and tolerability.

Does the weight come back after stopping?

STEP-4 showed significant regain in participants switched to placebo after a lead-in period. For many patients, the metabolic effect depends on continued therapy. Long-term outcomes after discontinuation depend heavily on the lifestyle changes consolidated during treatment.

Do I need labs before starting?

A careful program will document baseline labs, typically a metabolic panel, lipid panel, A1c, and sometimes a thyroid panel. The specific panel depends on your clinical picture.

Is semaglutide appropriate for everyone?

No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. These should be surfaced during intake, before therapy begins.

What if I’m already on insulin or a sulfonylurea?

Discuss dose adjustments with your prescriber. The glucose-dependent action of semaglutide means hypoglycemia risk increases when combined with these agents.

Can I use my HSA or FSA to pay for a compounded program?

It depends on your plan. Confirm the program’s invoicing format before enrolling to ensure the expense qualifies.

References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).

Important Notice

Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.